Biotech entity
Every one of those 1 sits in a single category, pharma. Core Molding Technologies is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Carvykti, all published on March 10, 2026.
Last mentioned: Jul 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Core Molding Technologies is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Carvykti, all published on March 10, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Carvykti. Shared-story counts are live from our verified record — not editorial picks.
Pipeline Update
Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.
Manufacturing Expansion
Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.
FY 2025 Earnings
Legend Biotech reports full-year results and commercial highlights.
Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.
Carvykti is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
